FindTrial
Sign In

antibody-drug conjugate therapy

PROCEDURE3 trials

Sponsors

MedImmune LLC, Mayo Clinic

Conditions

LeukemiaLymphomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRefractory Bladder Urothelial CarcinomaRefractory Renal Pelvis and Ureter Urothelial CarcinomaStage IV Bladder Cancer AJCC v7Stage IV Renal Pelvis and Ureter Cancer AJCC v7

Phase 1

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
SuspendedNCT00077493
MedImmune LLCLeukemia, Lymphoma
Start: 2004-01-31End: 2008-10-31Target: 95Updated: 2007-12-28
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
CompletedNCT00126646
MedImmune LLCLeukemia, Lymphoma
Start: 2005-06-30End: 2009-06-30Target: 24Updated: 2010-06-22

Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
RecruitingNCT07087860
Mayo ClinicMetastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma +3
Start: 2025-08-01End: 2028-08-07Target: 70Updated: 2025-12-09